X T L Biopharmaceuticals Ltd
TASE:XTLB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of X T L Biopharmaceuticals Ltd (XTLB) under the Base Case is 1.49 ILS per share. Compared with the current market price of 1.4 ILS, the stock appears Undervalued by 6% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What X T L Biopharmaceuticals Does
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process.
- Headquarters
- Israel IL
- Employees
- 33
- IPO date
- Sep 1, 2000
Continue XTLB Research
Decided on X T L Biopharmaceuticals? Get an email when XTLB reaches the price you’d buy at. Free with an account.
Other X T L Biopharmaceuticals listings
What is the Intrinsic Value of one XTLB stock?
The intrinsic value for X T L Biopharmaceuticals Ltd (XTLB) under the Base Case is 1.49 ILS.
Is XTLB stock undervalued or overvalued?
Compared with the current market price of 1.4 ILS, the stock appears Undervalued by 6% .